Literature DB >> 28782621

Yongdamsagan-tang, a traditional herbal formula, inhibits cell growth through the suppression of proliferation and inflammation in benign prostatic hyperplasia epithelial-1 cells.

Eunsook Park1, Mee-Young Lee2, Chang-Seob Seo2, Woo-Young Jeon2, Hyeun-Kyoo Shin3.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Benign prostatic hyperplasia (BPH), also called benign enlargement of the prostate, is a progressive disease that is observed in most elderly men. Yongdamsagan-tang, a traditional herbal formula, is used commonly for the treatment of inflammation-related diseases. Although the therapeutic efficacy of Yongdamsagan-tang against BPH in vivo was reported previously, its underlying mechanisms are not clearly understood. AIM OF THE STUDY: In this study, we investigated the effect of Yongdamsagan-tang water extract (YSTE) and its mechanism on the growth of human BPH epithelial BPH-1 cells.
MATERIALS AND METHODS: YSTE was extracted from 11 herbaceous plants and its chemical composition was analyzed by High-performance liquid chromatography (HPLC). YSTE was treated in the epithelial BPH-1 cell line and then cell lysates or supernant were used to evaluate cell viability, cell cycle, proliferation and cytokine production.
RESULTS: HPLC revealed that Baicalin and gentiopicroside were involved as the major compounds of YSTE. YSTE treatment in BPH-1 cells repressed cell viability in a dose-dependent manner. Regarding the inhibitory mechanisms of YSTE on cell growth, YSTE inhibited cell proliferation via a decrease in endogenous cyclin D1 protein levels and arrest at the S phase during cell-cycle progression. Furthermore, YSTE treatment in BPH-1 cells suppressed prostaglandin E2 production and cyclooxygenase-2 (COX-2) protein levels. The secretion of the proinflammatory cytokines, interleukin-8 and interleukin-6, was also reduced by YSTE treatment.
CONCLUSIONS: YSTE in BPH-1 cells showed antiproliferative and anti-inflammatory activities via cell-cycle arrest and downregulation of COX-2 expression, respectively. Taken together, the results of the present study will enhance our understanding of the mechanisms underlying the effect of YSTE in BPH.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  BPH-1 cells; Benign prostatic hyperplasia; Inflammation; Proliferation; Traditional herbal formula; Yongdamsagan-tang

Mesh:

Substances:

Year:  2017        PMID: 28782621     DOI: 10.1016/j.jep.2017.08.002

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  4 in total

1.  Elucidating the Synergistic Effect of Multiple Chinese Herbal Prescriptions in the Treatment of Post-stroke Neurological Damage.

Authors:  Anqi Xu; Zhuo-Hua Wen; Shi-Xing Su; Yu-Peng Chen; Wen-Chao Liu; Shen-Quan Guo; Xi-Feng Li; Xin Zhang; Ran Li; Ning-Bo Xu; Ke-Xin Wang; Wen-Xing Li; Dao-Gang Guan; Chuan-Zhi Duan
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

2.  Combination therapy with tamsulosin and traditional herbal medicine for lower urinary tract symptoms due to benign prostatic hyperplasia: A double-blinded, randomized, pilot clinical trial.

Authors:  Chung Lyul Lee; Hyeun-Kyoo Shin; Ji Yong Lee; Ojin Kwon; Chang-Seob Seo; Ae-Ran Kim; Bok-Nam Seo; Seung Woo Yang; Ki Hak Song; Jae Sung Lim; Jong Mok Park; Yong Gil Na; Ju Hyun Shin
Journal:  Int J Urol       Date:  2022-03-16       Impact factor: 2.896

3.  Ethanol Extract of Evodia rutaecarpa Attenuates Cell Growth through Caspase-Dependent Apoptosis in Benign Prostatic Hyperplasia-1 Cells.

Authors:  Eunsook Park; Mee-Young Lee; Chang-Seob Seo; Ji-Hye Jang; Yong-Ung Kim; Hyeun-Kyoo Shin
Journal:  Nutrients       Date:  2018-04-22       Impact factor: 5.717

4.  Resveratrol Attenuates the Proliferation of Prostatic Stromal Cells in Benign Prostatic Hyperplasia by Regulating Cell Cycle Progression, Apoptosis, Signaling Pathways, BPH Markers, and NF- κB Activity.

Authors:  Jowon Jang; Junhui Song; Jiyun Lee; Sung-Kwon Moon; Bokyung Moon
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.